Advertisement

Antihypertonika

  • Manfred Anlauf
Chapter

Zusammenfassung

Als spezielle Antihypertonika werden in diesem Kapitel neben Atpharezepto-renblockern und zentral wirkenden Antisympathikotonika in erster Linie Kombinationspräparate von Betarezeptorenblockem, Calciumantagonisten und Reserpin dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, München.Google Scholar
  2. Anlauf M, Hense HW (2003): Echte und vermeintliche Sparpotenziale in der Hochdrucktherapie — Neues aus dem Zauberhut. Dtsch Med Wschr 128:1557–1559.PubMedCrossRefGoogle Scholar
  3. Anlauf M, Tholl U, Hirche H, Weber F (2001): A silent revolution in blood pressure measurement? Some late remarks in regards to the HOT study. J Hum Hypertension 15:649–651.CrossRefGoogle Scholar
  4. Anlauf M, Weber F (2004): Rauchen und Hypertonie (im Druck)Google Scholar
  5. Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage AVP.Google Scholar
  6. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, Dawes M, Ebbs D, Farmer A, Robinson J (1994): Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 12:1053–1060.PubMedCrossRefGoogle Scholar
  7. Barmer Information (2003): Pressekonferenz der Barmer „Mehr Qualität statt weniger Leistung“, 23. April 2003.Google Scholar
  8. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA et al (2003): Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy. Ann Intern Med 138: 542–549.PubMedGoogle Scholar
  9. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB et al for the CONVINCE Research Group (2003): Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 289: 2073–2082.PubMedCrossRefGoogle Scholar
  10. Bock KD, Anlauf M (1984): Die Qual der Wahl — das Dilemma der Hochdrucktherapie. Münch Med Wochenschr 16:477–479.Google Scholar
  11. Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560–2571.PubMedCrossRefGoogle Scholar
  12. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N et al (2003): Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667PubMedCrossRefGoogle Scholar
  13. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR et al, ALLHAT Collaborative Research Group (2002): Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 4: 393–404.CrossRefGoogle Scholar
  14. Deutsche Hochdruckliga (2003): Empfehlungen zur Therapie der arteriellen Hypertonie. HeidelbergGoogle Scholar
  15. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ (1999): Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353:2008–2013.PubMedCrossRefGoogle Scholar
  16. Guidelines Committee (2003): 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011–1053.CrossRefGoogle Scholar
  17. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D et al (1998): Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762.PubMedCrossRefGoogle Scholar
  18. Jackson PR, Ramsay LE (2002): The United States JNC VI and British Hypertension Society Guideline. The International WHO/ISH Guideline. First-line treatment for hypertension. Eur Heart J 23:179–182.PubMedCrossRefGoogle Scholar
  19. Law MR, Wald NJ, Morris JK, Jordan RE (2003): Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:1427–1434PubMedCrossRefGoogle Scholar
  20. Luft FC (2001): Recent clinical trial highlights in hypertension. Curr Hypertens Rep 3:133–138.PubMedCrossRefGoogle Scholar
  21. Medical Research Council Working Party (1985): MRC trial of treatment of mild hypertension. Brit Med J 291: 97–104.CrossRefGoogle Scholar
  22. Messerli FH, Grossman E, Goldbourt U (1998): Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279:1903–1907.PubMedCrossRefGoogle Scholar
  23. Middeke M, Anlauf M, Baumgart P, Franz A, Krönig B, Schrader J, Schulte KL (1998): Ambulante 24h-Blutdruckmessung. (ABDM). DMW 123:1426–1430.Google Scholar
  24. Neal B, MacMahon S, Chapman N for the Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964.PubMedCrossRefGoogle Scholar
  25. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, for the Treatment of Mild Hypertension Study Research Group (1993): Treatment of Mild Hypertension Study Final Results. JAMA 270: 713–724.PubMedCrossRefGoogle Scholar
  26. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD (2000): Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356:1942–1943.CrossRefGoogle Scholar
  27. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD et al (2002): Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 3:10.PubMedCrossRefGoogle Scholar
  28. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W for the PREVENT Investigators (2000): Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102: 1503–1510.PubMedCrossRefGoogle Scholar
  29. PREMIER Collaborative Research Group (2003): Effects of comprehensive Lifestyle Modifikation on Blood Pressure Control. JAMA 289:2083–2093CrossRefGoogle Scholar
  30. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS (2003): Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 289:2534–2544.PubMedCrossRefGoogle Scholar
  31. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG et al (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRefGoogle Scholar
  32. Staessen JA, Gasowski J, Wang Lj G, Thijs L, et al (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872.PubMedCrossRefGoogle Scholar
  33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967–1975.CrossRefGoogle Scholar
  34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.CrossRefGoogle Scholar
  35. Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10:1103–1109.CrossRefGoogle Scholar
  36. Weber MA, Julius S, Kjeldsen SE, Brunner HR (2004): Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363: 2049–2054.PubMedCrossRefGoogle Scholar
  37. Williams B, Poulter NR, Brown MJ, Davis M et al (2004), Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18:139–185.PubMedCrossRefGoogle Scholar
  38. Wing LMH, Reid MC, Ryan P, Beilin LJ et al for the Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angioten-sin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592.PubMedCrossRefGoogle Scholar
  39. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW et al (2003): Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289:2363–2369.PubMedCrossRefGoogle Scholar
  40. Zanchetti A, Hansson L, Clement D, Elmfeldt D et al (2003): Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 21: 797–804.PubMedCrossRefGoogle Scholar
  41. Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and Clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522–1530.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Manfred Anlauf
    • 1
  1. 1.Bremerhaven

Personalised recommendations